CMS certification 050348
UCI Health-Orange
101 City Drive South, Orange, CA 92868
UCI Health-Orange has a CMS overall rating of 4 out of 5 stars. 67% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 9 and worse on 2. Emergency patients spend a median of 5 h 18 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 575 completed surveys, 16% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as very high; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | CA | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 363 visits sampled · US median for EDs of the same volume: 3 h 21 min | 5 h 18 min | 2 h 54 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 17 visits sampled | 15 h 28 min | 4 h 20 min | 4 h 17 min |
| Left before being seen Lower is better · 64,860 patients | 2% | 2% | 2% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 326 patients | 66% | 70% | 65% |
How UCI Health-Orange compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| UCI Health-OrangeThis hospital | 4/5 | 67% | 5 h 18 min | 9 better 2 worse |
| Providence St. Joseph HospitalSame city | 4/5 | 71% | 3 h 34 min | 2 better 1 worse |
| Chapman Global Medical CenterSame city | 2/5 | 48% | 2 h 31 min | 1 worse |
| Garden Grove Hospital & Medical CenterSame county · Garden Grove | 2/5 | 54% | 2 h 14 min | 1 better 1 worse |
| Providence St. Jude Medical CenterSame county · Fullerton | 4/5 | 78% | 4 h 23 min | 5 better 1 worse |
| Kaiser Foundation Hospital - Orange County - AnaheimSame county · Anaheim | 4/5 | 81% | — | 1 better |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Orange.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 4,269 cases | Too few cases | 3% | 3.9% |
| Heart attack 104 cases | Too few cases | 12.2% | 11.9% |
| Heart failure 331 cases | Too few cases | 10.3% | 11.1% |
| Pneumonia 416 cases | Too few cases | 15.1% | 15.2% |
| Stroke 330 cases | Too few cases | 10.4% | 11.9% |
| COPD 59 cases | Too few cases | 7.2% | 8.6% |
| Heart bypass surgery (CABG) 60 cases | Too few cases | 3.3% | 2.4% |
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 0.9 likely 0.67 – 1.13 | 1 |
| After hip or knee replacement 170 cases | Too few cases | 3.5% | 4.1% |
| Deaths after a serious but treatable surgical complication 170 cases | Better | 82.98 per 1,000 likely 46.2 per 1,000 – 119.76 per 1,000 | 173.3 per 1,000 |
| Pressure ulcers (bed sores) 7,232 cases | No different | 0.28 per 1,000 likely 0 per 1,000 – 0.77 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 8,263 cases | No different | 0.14 per 1,000 likely 0 per 1,000 – 0.33 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 8,703 cases | No different | 0.19 per 1,000 likely 0.01 per 1,000 – 0.37 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 2,756 cases | No different | 2.52 per 1,000 likely 1.33 per 1,000 – 3.71 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 1,647 cases | No different | 1.95 per 1,000 likely 0.57 per 1,000 – 3.32 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 1,643 cases | No different | 7.15 per 1,000 likely 2.82 per 1,000 – 11.48 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 2,934 cases | Worse | 5.44 per 1,000 likely 3.82 per 1,000 – 7.06 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 1,680 cases | No different | 4.78 per 1,000 likely 2.24 per 1,000 – 7.33 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 871 cases | No different | 1.98 per 1,000 likely 0.61 per 1,000 – 3.36 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 2,297 cases | No different | 1.06 per 1,000 likely 0.25 per 1,000 – 1.87 per 1,000 | 1.06 per 1,000 |
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | Better | 0.56 likely 0.35 – 0.85 | 1 |
| Urinary tract infections from catheters (CAUTI) | Better | 0.42 likely 0.25 – 0.67 | 1 |
| Surgical site infections after colon surgery | Better | 0.45 likely 0.2 – 0.89 | 1 |
| Surgical site infections after abdominal hysterectomy | No different | 0.55 likely 0.03 – 2.69 | 1 |
| MRSA bloodstream infections | Better | 0.36 likely 0.14 – 0.74 | 1 |
| C. diff intestinal infections | Better | 0.55 likely 0.4 – 0.74 | 1 |
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after a heart attack 165 cases | Too few cases | 14.6% | 14.4% |
| Readmitted after heart failure 556 cases | Too few cases | 20.8% | 21.3% |
| Readmitted after pneumonia 556 cases | Too few cases | 16.8% | 17.3% |
| Readmitted after COPD 110 cases | Too few cases | 21% | 20% |
| Readmitted after heart bypass surgery 64 cases | Too few cases | 12.9% | 11% |
| Readmitted after hip or knee replacement 200 cases | Too few cases | 5.8% | 5.8% |
| Days back in hospital after a heart attack 113 cases | Too few cases | 75.5 days per 100 | — |
| Days back in hospital after heart failure 391 cases | Too few cases | 0 days per 100 | — |
| Days back in hospital after pneumonia 436 cases | Too few cases | -4.4 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 2,457 cases | No different | 10.8 per 1,000 likely 8.6 per 1,000 – 13.8 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 846 cases | No different | 11.8 per 100 likely 10 per 100 – 14 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 846 cases | No different | 5.2 per 100 likely 4.1 per 100 – 6.6 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 1,287 cases | Better | 0.8 likely 0.6 – 1 | — |
1 more measure had too few cases here to report.
Clinicians registered at this address
1,773 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 468 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Anesthesiology | 129 |
| Emergency Medicine | 126 |
| Internal Medicine | 104 |
| Nurse Practitioner | 79 |
| Diagnostic Radiology | 75 |
| Nurse Anesthetist, Certified Registered | 74 |
| Psychiatry | 53 |
| Hospitalist | 52 |
| Physician Assistant | 51 |
| Obstetrics & Gynecology | 44 |
| Urology | 43 |
| Hematology & Oncology | 41 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $16M
- 2020 $19.4M
- 2021 $20.8M
- 2022 $17.3M
- 2023 $22.4M
- 2024 $25.5M
- 2025 $23M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $1.5M | 76 |
| Space rental and facility fees | $460,074 | 80 |
| Education | $177,592 | 60 |
| Speaking, teaching and other services | $136,471 | 19 |
| Medical devices and supplies on long-term loan | $86,126 | 13 |
| Gifts | $22,374 | 4 |
| Debt forgiveness | $9,738 | 7 |
| Charitable contributions | $7,000 | 4 |
| Royalties and licensing fees | $6,040 | 2 |
| Food and beverage | $255 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Merck Sharp & Dohme LLC | $2.8M | 40 |
| Pfizer INC. | $1.9M | 100 |
| Janssen Research & Development, LLC | $1.6M | 123 |
| AstraZeneca Pharmaceuticals LP | $1.5M | 21 |
| Genentech, Inc. | $1.5M | 78 |
| Amgen Inc. | $1.1M | 25 |
| Abbvie INC. | $1M | 113 |
| AstraZeneca UK Limited | $798,161 | 5 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Ca… Merck Sharp & Dohme LLC | $805,622 |
| IMMUNE CHECKPOINT INHIBITOR COMBINATIONS WITH AXITINIB IN 1L LOCALLY ADVANCED OR METASTATIC RCC Genentech, Inc. | $642,814 |
| A Phase II Open-label Multi-centre Study to Evaluate Safety Tolerability Efficacy PK and Immunogenicity of AZD0901 as Monotherapy and in Combination … AstraZeneca Pharmaceuticals LP | $633,536 |
| A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Pos… Merck Sharp & Dohme LLC | $541,676 |
| A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With… Eisai Inc. | $539,865 |
| An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment in Participants with Advance… Merck Sharp & Dohme LLC | $492,742 |
| A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed… E.R. Squibb & Sons, L.L.C. | $480,635 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER PFIZER INC. | $460,769 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about UCI Health-Orange
Is UCI Health-Orange a good hospital?
UCI Health-Orange has a CMS overall rating of 4 out of 5 stars. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 9 and worse on 2. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend UCI Health-Orange?
67% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 575 completed HCAHPS surveys.
How long is the wait in the UCI Health-Orange emergency room?
Emergency patients spend a median of 5 h 18 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with very high patient volume, like this one, the median is 3 h 21 min. 2% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does UCI Health-Orange receive money from drug and device companies?
Drug and device makers reported $23M in payments to UCI Health-Orange for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.